Trial of Covid-19 drug given via inhaler ‘very promising’, say scientists - THE MEDICAL VIDEO

Synairgen announces positive results from trial of SNG001 in hospitalised COVID-19 patients

- Patients who received SNG001 had a 79% lower risk of developing severe disease compared to placebo .

- SNG001, an inhaled of IFN-β1a for nebulisation as a broad-spectrum antiviral to treat/prevent severe viral lung infection's .

- SNG001 , IFN-β1a Well tolerated in asthma/COPD patients / Covid19 patients .

What is IFN-β1a

IFN-β is used in the form of natural fibroblast or recombinant preparations (interferon beta-1a and innterferon beta-1b) and exerts antiviral and antiproliferative properties similar to those of interferon alfa. Although its efficacy has been debated .

How IFN-β1a works

1- Causes controlled cell death in cells that cannot stop the infection, preventing the spread of the infection

2- Drives the expression of 100s of antiviral proteins, which act at different stages of the viral replication cycle, resulting in broad antiviral protection

3- Activates immune cells to eliminate virus-infected cells .

Antiviral activity of interferon (IFN) β-1a. Cytopathic effect (CPE) on infected cells treated with increasing doses of Interferon beta

IFN-β1a highly effective in inhibiting in vitro SARS-CoV-2 replication at clinically

achievable concentration when administered after virus infection

• This trial of hospitalised COVID-19 patients showed that SNG001:

1- Reduced the odds of developing severe

disease by 79%

2- Increased the likelihood of recovery 2 to 3-fold

3-Significantly reduced breathlessness

4- Encouraging hospital discharge data

For details visit official site

https://www.synairgen.com/

Trial of Covid-19 drug given via inhaler ‘very promising’, say scientists

Synairgen announces positive results from trial of SNG001 in hospitalised COVID-19 patients

- Patients who received SNG001 had a 79% lower risk of developing severe disease compared to placebo .

- SNG001, an inhaled of IFN-β1a for nebulisation as a broad-spectrum antiviral to treat/prevent severe viral lung infection's .

- SNG001 , IFN-β1a Well tolerated in asthma/COPD patients / Covid19 patients .

What is IFN-β1a

IFN-β is used in the form of natural fibroblast or recombinant preparations (interferon beta-1a and innterferon beta-1b) and exerts antiviral and antiproliferative properties similar to those of interferon alfa. Although its efficacy has been debated .

How IFN-β1a works

1- Causes controlled cell death in cells that cannot stop the infection, preventing the spread of the infection

2- Drives the expression of 100s of antiviral proteins, which act at different stages of the viral replication cycle, resulting in broad antiviral protection

3- Activates immune cells to eliminate virus-infected cells .

Antiviral activity of interferon (IFN) β-1a. Cytopathic effect (CPE) on infected cells treated with increasing doses of Interferon beta

IFN-β1a highly effective in inhibiting in vitro SARS-CoV-2 replication at clinically

achievable concentration when administered after virus infection

• This trial of hospitalised COVID-19 patients showed that SNG001:

1- Reduced the odds of developing severe

disease by 79%

2- Increased the likelihood of recovery 2 to 3-fold

3-Significantly reduced breathlessness

4- Encouraging hospital discharge data

For details visit official site

https://www.synairgen.com/

No comments

Subscribe to: Post Comments (Atom)